Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma

Autor: Keizo Horibe, Masaru Kondo, Yuji Miyajima, Minoru Fukuda, Kimikazu Matsumoto, Yoshiko Miyashita, Jun Inaba
Rok vydání: 2001
Předmět:
Cancer Research
Pathology
Neoplasm
Residual
medicine.medical_treatment
Adrenal Gland Neoplasms
Hematopoietic stem cell transplantation
Gastroenterology
Neuroblastoma
Antineoplastic Combined Chemotherapy Protocols
Medicine
Life Tables
RNA
Neoplasm
Neoplasm Metastasis
Child
Etoposide
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation
Bone Marrow Examination
Prognosis
Combined Modality Therapy
Neoplasm Proteins
medicine.anatomical_structure
Treatment Outcome
Oncology
Chemotherapy
Adjuvant
Vincristine
Child
Preschool
medicine.drug
medicine.medical_specialty
Cyclophosphamide
Tyrosine 3-Monooxygenase
Disease-Free Survival
Internal medicine
Biomarkers
Tumor
Humans
Ifosfamide
RNA
Messenger
Retroperitoneal Neoplasms
Neoplasm Staging
Chemotherapy
business.industry
medicine.disease
Minimal residual disease
Survival Analysis
Doxorubicin
Pediatrics
Perinatology and Child Health
Bone marrow
Cisplatin
business
Follow-Up Studies
Zdroj: Medical and pediatric oncology. 36(1)
ISSN: 0098-1532
Popis: Background We have determined whether sequential molecular detection of minimal residual disease (MRD) in bone marrow (BM) could predict the outcome of patients with advanced neuroblastoma (NB). Procedure Bone marrow samples from 19 patients over 12 months of age with stage 4 neuroblastoma were sequentially examined for tumor cell contamination by detecting tyrosine hydroxylase (TH) mRNA using reverse transcription-polymerase chain reaction (RT-PCR). All patients received repetitive multi-drug chemotherapy including cisplatin, cyclophosphamide or ifosphamide, adriamycin, and etoposide or vincristine. Seventeen patients received myeloablative therapy with hematopoietic stem cell transplantation after achieving complete remission. Results All but one patient were histologically positive for tumor cells in BM samples at diagnosis, and they became negative for tumor cells within 3 months histologically. By the RT-PCR analysis, all patients were positive for TH mRNA in BM samples at diagnosis, and they became negative for TH mRNA 1 to 13 months after the start of chemotherapy. Six patients whose BM samples became negative for TH mRNA within 4 months after the start of chemotherapy remained alive without evidence of disease (median 61 months, range 20–76). In contrast, 12 of 13 patients whose BM samples remained positive at that time developed relapse and 10 of them died of disease (median 24 months, range 13–43). There was a statistically significant difference in survival between the two groups (P < 0.05). No significant difference of clinical characteristics by the MRD positivity at 4 months after the start of chemotherapy. Conclusions Persistence of MRD in BM at 4 months after the start of chemotherapy could predict poor prognosis in advanced neuroblastoma. Med. Pediatr. Oncol. 36:203–204, 2001. © 2001 Wiley-Liss, Inc.
Databáze: OpenAIRE
Externí odkaz: